Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

IMPORTANCE: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). OBJECTIVE: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA
Päätekijät: Locatelli, Franco, Zugmaier, Gerhard, Rizzari, Carmelo, Morris, Joan D., Gruhn, Bernd, Klingebiel, Thomas, Parasole, Rosanna, Linderkamp, Christin, Flotho, Christian, Petit, Arnaud, Micalizzi, Concetta, Mergen, Noemi, Mohammad, Abeera, Kormany, William N., Eckert, Cornelia, Möricke, Anja, Sartor, Mary, Hrusak, Ondrej, Peters, Christina, Saha, Vaskar, Vinti, Luciana, von Stackelberg, Arend
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2021
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7926287/
https://ncbi.nlm.nih.gov/pubmed/33651091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2021.0987
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia